



Formulary Changes Announced

Fourth quarter changes to the Independent Health Drug formularies are summarized below and currently in effect unless otherwise noted.

NPG/NPB - Non-Preferred Generic/Brand
 PG/PB - Preferred Generic/Brand
 NF – Non-Formulary
 SP - Specialty Pharmacy
 PA - Prior Authorization
 ST – Step Therapy

QL – quantity Limits
 SC – subcutaneous
 IM - intramuscular
 inj – injection
 tab – tablet
 cap – capsule
 ophm- ophthalmic

soln – solution
 susp – suspension
 MDI-metered-dose inhalation aerosol
 ODT – orally-disintegrating tablet
 LA - available only at certain pharmacies
 G - Generic (T2) for Medicare

Changes to Drug Formulary I (DF1), FEHB Formulary, and Pharmacy Benefit Dimensions Formulary		
Medications Added to Formulary 1/1/2024	Medications Non-Formulary 1/1/2024	Changes to Formulary 1/1/2024
Agamree (vamorolone) oral susp, NPB, PA w/embedded ST, SP, LA Breo Ellipta 50-25 mcg/inhalation PB Bimzelx (bimekizumab-bkzx) SC inj, NPB, PA w/ST, SP Kalydeco 5.8 mg granules, PB, PA Liftulo (ritilecitinib) cap, NPB PA SP Ojjaara (momelotinib) tab, NPB, PA, SP, LA Opfolda (miglustat) cap, NPB, PA, SP Rivfloza (nedosiran) SC inj, NPB, PA, SP Sohonos (palovarotene) cap, NPB, PA Velsipity (etrasimod) tab, NPB, PA w/embedded ST Voquezna (vonoprazan) tab, NPB, PA w/embedded ST Xphozah (tenapanor) tab, NPB, ST Zilbrysq (zilucoplan) SC inj, NPB, PA, SP, LA	Cabtreo (clindamycin/adapalene/benzoyl peroxide) topical gel Coxanto (oxaprozin) cap Entyvio (vedolizumab) SC inj Exxua (gepirone) ER tab glipizide 2.5 mg tablets Likmez (metronidazole) oral susp Omvoh (mirikizumab-mrkz) SC inj Ozobax DS (baclofen oral solution) 10 mg/5 mL Ryzumvi (phentolamine) ophm soln trientine 500 mg capsules Wezlana (ustekinumab-auub) SC inj Zymfentra (infliximab-dyyb) SC inj	carbidopa from T3 to T1 metaxalone 400mg tab from T3 to NF (DF1 3/1/2024, FEHB 1/1/2025) metaxalone 800mg tab from T3 to T1 orphenadrine ER from T3 to T1 Pentasa 500 mg (brand) NF to T2 pheburane from NF to T3 PA pyridostigmine oral soln from NF to T1 rasagiline T1 remove PA Ravicti from T3PA to NF (DF1 3/1/2024; FEHB 1/1/2025) Zelapar ODT T2 to NF (9/30/2023)

Changes to Drug Formulary II (DF2), Drug Formulary III (DF3), and Essential Plan Formulary (EPF)		
Medications Added to Formulary 1/1/2024	Medications Non-Formulary 1/1/2024	Changes to Formulary 1/1/2024
Agamree (vamorolone) oral susp, NPB, PA w/embedded ST, SP, LA Breo Ellipta 50-25 mcg/inhalation PB Bimzelx (bimekizumab-bkzx) SC inj, NPB, PA w/ST, SP Kalydeco 5.8 mg granules, PB, PA Liftulo (ritilecitinib) cap, NPB PA SP Ojjaara (momelotinib) tab, NPB, PA, SP, LA Opfolda (miglustat) cap, NPB, PA, SP Rivfloza (nedosiran) SC inj, NPB, PA, SP Sohonos (palovarotene) cap, NPB, PA Velsipity (etrasimod) tab, NPB, PA w/embedded ST Voquezna (vonoprazan) tab, NPB, PA w/embedded ST Xphozah (tenapanor) tab, NPB, ST Zilbrysq (zilucoplan) SC inj, NPB, PA, SP, LA	Cabtreo (clindamycin/adapalene/benzoyl peroxide) topical gel Coxanto (oxaprozin) cap Entyvio (vedolizumab) SC inj Exxua (gepirone) ER tab glipizide 2.5 mg tablets Likmez (metronidazole) oral susp Omvoh (mirikizumab-mrkz) SC inj Ozobax DS (baclofen oral solution) 10 mg/5 mL Qlosi (pilocarpine) ophm soln Ryzumvi (phentolamine) ophm soln trientine 500 mg capsules Wezlana (ustekinumab-auub) SC inj Zymfentra (infliximab-dyyb) SC inj	carbidopa from T2 to T1 metaxalone 400mg tab from T2 to NF (3/1/2024) metaxalone 800mg tab from T2 to T1 Pentasa 500 mg (brand) NF to T2 pheburane from NF to T3 PA pyridostigmine oral soln from NF to T1 rasagiline T2 to T1 remove PA Ravicti from T3PA to NF (3/1/2024) Zelapar ODT T2 to NF (9/30/2023)

Changes to Child Health Plus Formulary		
Medications Added to Formulary 1/1/2024	Medications Non-Formulary 1/1/2024	Changes to Formulary 1/1/2024
Agamree (vamorolone) oral susp, PB, PA w/embedded ST, SP, LA Kalydeco 5.8 mg granules, PB, PA	Bimzelx (bimekizumab-bkzx) SC inj Breo Ellipta 50-25 mcg/inhalation PB Cabtreo (clindamycin/adapalene/benzoyl peroxide) topical gel Coxanto (oxaprozin) cap Entyvio (vedolizumab) SC inj Exxua (gepirone) ER tab glipizide 2.5 mg tablets Likmez (metronidazole) oral susp Ojjaara (momelotinib) tab Omvoh (mirikizumab-mrkz) SC inj Opfolda (miglustat) cap Ozobax DS (baclofen oral solution) 10 mg/5 mL Qlosi (pilocarpine) ophm soln Rivfloza (nedosiran) SC inj Ryzumvi (phentolamine) ophm soln Sohonos (palovarotene) cap trientine 500 mg capsules Velsipity (etrasimod) tab Voquezna (vonoprazan) tab Wezlana (ustekinumab-auub) SC inj Xphozah (tenapanor) tab Zilbrysq (zilucoplan) SC inj Zymfentra (infliximab-dyyb) SC inj	metaxalone 400mg tab from T1 to NF (3/1/2024) metaxalone 800mg tab from T2 to T1 pyridostigmine oral soln from NF to T1 rasagiline T1 remove PA

Changes to Medicare Formulary		
Medications Added to Formulary 1/1/2024	Medications Non-Formulary 1/1/2024	Changes to Formulary 1/1/2024
Kalydeco 5.8 mg granules, PB, PA Ojjaara (mometolitinib) tab, NPB, PA, SP, LA Opfolda (miglustat) cap: NPB, PA, SP Rivfloza (nedosiran) SC inj, NPB, PA, SP Sohonos (palovarotene) cap, NPB, PA Velsipity (etrasimod) tab, NPB, PA w/embedded ST Voquezna (vonoprazan) tab, NPB, PA w/embedded ST Xphozah (tenapanor) tab, NPB, ST Zilbrysq (zilucoplan) SC inj, NPB, PA, SP, LA	Agamree (vamorolone) oral susp Bimzelx (bimekizumab-bkzx) SC inj Cabtreo (clindamycin/adapalene/benzoyl peroxide) topical gel Coxanto (oxaprozin) cap Exxua (gepirone) ER tab glipizide 2.5 mg tablets Likmez (metronidazole) oral susp OmvoH (mirikizumab-mrkz) SC inj Ozobax DS (baclofen oral solution) 10 mg/5 mL Qlosi (pilocarpine) ophm soln Ryzumvi (phentolamine) ophm soln trientine 500 mg capsules Wezlana (ustekinumab-auub) SC inj Zymfentra (infliximab-dyyb) SC inj	pheburane from NF to T5 PA (1/1/2025) Ravicti from T5PA to NF (1/1/2025)

Policy updates of drugs with new indications:

Drugs with new indications:

Brand name	Generic name	New indication(s)	Coverage changes
Abrilada	adalimumab-afzb	uveitis	None
Bosulif	bosutinib	AL on chronic phase Ph+ CML lowered to 1 year of age	PA policy changes
Braftovi	encorafenib	BRAF V600E (+) metastatic NSCLC with binimetinib	PA policy changes
Comirnaty	COVID-19 vaccine, mRNA	2023-2024 updated formulation	None
Cosentyx	secukinumab	hidradenitis suppurativa	PA policy changes
Enbrel	etanercept	active juvenile psoriatic arthritis ages 2 and up	PA policy changes
Hulio	adalimumab-fkjp	uveitis	None
Hyrimoz	adalimumab-adaz	uveitis	None
Idacio	adalimumab-aacf	hidradenitis suppurativa	None
Idacio	adalimumab-aacf	uveitis	None
llaris	canakinumab	gout flares refractory to other medications	PA policy changes
Ingrezza	valbenazine	Huntington's disease chorea	PA policy changes
Jardiance	empagliflozin	reduce risk of eGFR decline, ESRD, CV death, and hospitalization in adults with CKD at risk of progression	None
Keytruda	pembrolizumab	resectable NSCLC w/platinum neoadjuvant & after surgery	PA policy changes
Keytruda	pembrolizumab	loc adv/metastatic biliary tract Ca w/cisplatin + gemcitabine	PA policy changes
Mekinist	trametinib	BRAF V600E (+) solid tumors lower AL down to 1 year of age	PA policy changes
Mektovi	binimetinib	BRAF V600E (+) metastatic NSCLC with encorafenib	PA policy changes
Opdivo	nivolumab	adjuvant tx of stage IIB/C completely resected melanoma	PA policy changes
Orencia	abatacept	lower AL on PsA indication down to 2 years of age	PA policy changes
Reblozyl	luspatercept-aamt	anemia w/o previous ESA use in up to intermediate-risk MDS	PA policy changes
Rozlytrek	entrectinib	lower AL down to 1 month of age for solid tumor indication	PA policy changes
Spikevax	COVID-19 vaccine, mRNA	2023-2024 updated formulation	None
Tafinlar	dabrafenib	BRAF V600E (+) solid tumors lower AL down to 1 year of age	PA policy changes
Temodar	temozolomide	adjuvant treatment of newly-diagnosed astrocytoma	None
Tibsovo	ivosidenib	rel/refr IDH1-mutated myelodysplastic syndrome	PA policy changes
Vabysmo	faricimab-svoa	diabetic macular edema after retinal vein occlusion	PA policy changes
Veltassa	patiromer	lower AL down to 12 years of age	AL changes
Voxzogo	vosoritide	lower AL removed; can be used in all pediatric patients	PA policy changes
Yusimry	adalimumab-aqvh	uveitis	None
Zoryve	roflumilast cream	lower AL down to 6 years of age	PA policy changes

Medical: (effective 1/1/2024)

1. **Hepzato** (melphalan) – bundled with hospitalization
2. **Loqtorzi** (toripalimab-tpzi) intravenous injection - Medical, PA
3. **Aphexda** (motixafortide) subcutaneous injection - Medical, PA w/ST
4. **Cosentyx** (secukinumab) intravenous injection - Medical, PA
5. **Eylea HD** (aflibercept) intravitreal injection - Medical, PA
6. **OmvoH** (mirikizumab-mrkz) intravenous injection - Medical, PA
7. **Veopoz** (pozelimab-bbfg) intravenous infusion or subcutaneous injection – Medical, PA
8. **Pombiliti** (cipaglucosidase alfa-atga) intravenous injection– Medical, PA
9. **Penbraya** (meningococcal groups A, B, C, W, and Y vaccine) intramuscular injection - Medical, AL 10-25 y
10. **Tyruko** (natalizumab-sztn) intravenous injection - Medical, PA
11. **Tofidence** (tocilizumab-bavi) intravenous injection- Medical, PA
12. **Wezlana** (ustekinumab-auub) intravenous injection - Medical, PA
13. **Daxxify** (daxibotulinumtoxinA-lanm) intramuscular injection - Medical, PA
14. **Focinvez** (fosaprepitant) intravenous injection - Medical, PA
15. **Technegas** (technetium Tc 99m-labeled carbon inhalation aerosol) – Medical

New generics:

Brands now non-formulary unless otherwise indicated. For Medicaid, medical drugs will be covered as Commercial unless otherwise specified below.

Brand name	Generic name	Generic tier placement/utilization management			
		Commercial/ FEHB	Exch/Small/EBP	Medicaid	Medicare Indiv/PDP
Alphagan-P	brimonidine 0.1% ophth sol	T1	NF	NF	T2/T1
Balcoltra	Joyeaux (oral contraceptive)	T1	T1	T1	T2/T1
Flovent HFA	fluticasone HFA	T1	T1	T1	T2/T1 (eff. 1/1/24)
Mydayis	amphetamine/dextroamphet	T3 ST	T3 ST	NF	NF/NF
Onexton	clindamycin/benzoyl peroxide	NF	NF	NF	NF/NF
Spiriva	tiotropium capsule	NF	NF	NF	NF/NF
Votrient	pazopanib	T1 PA	T2 PA	NF	T5 PA/T1 PA
Vyvanse	lisdexamfetamine	T1	T1	NF	T4/T1